Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Executive Summary
2.1 A Large Therapy Area with Varying Unmet Needs Across Indications
2.2 A Large Pipeline with a High Degree of First-in-Class Innovation
2.3 A Number of Highly Promising First-in-Class Versatile Oncology Pipeline Targets
3 The Case for Innovation in the Oncology Market
3.1 Growing Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Product Developments Remain Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
3.5 Sustained Innovation
3.6 Report Guidance
4 Clinical and Commercial Landscape
4.1 Therapy Area Overview
4.1.1 Epidemiology
4.1.2 Etiology
4.1.3 Pathophysiology
4.1.4 Diagnosis
4.1.5 Prognosis and Disease Staging
4.2 Treatment Options
4.2.1 Surgery and Radiation Therapy
4.2.2 Chemotherapy
4.2.3 Hormonal Therapies
4.2.4 Targeted Therapies
4.3 Overview of Marketed Products for Oncology
4.4 Current Unmet Needs across the Oncology Markets
5 Assessment of Pipeline Product Innovation
5.1 Oncology Pipeline by Phase, Molecule Type and Molecular Target
5.2 Comparative Distribution of Programs between the Oncology Market and Pipeline by Therapeutic Target Family
5.3 First-in-Class and Versatile Pipeline Programs
5.3.1 First-in-Class Oncology Products by Phase, Molecule Type and Molecular Target
5.3.2 Versatility of First-in-Class Pipeline Products
6 Signaling Pathways, Disease-Causing Mutations and Versatile First-in-Class Molecular Target Integration
6.1 The Complexity of Signaling Networks in Oncology
6.2 Signaling Pathways, Disease-Causing Mutations and Versatile First-in-Class Molecular Target Integration
6.3 Versatile First-in-Class Target Matrix Assessment
7 Versatile First-in-Class Target Assessment**
7.1 Pipeline Programs that Target X
7.2 Pipeline Programs that Target X
7.3 Pipeline Programs that Target X
7.4 Pipeline Programs that Target X
7.5 Pipeline Programs that Target X
7.6 Pipeline Programs that Target X
7.7 Pipeline Programs that Target X
7.8 Pipeline Programs that Target X
7.9 Pipeline Programs that Target X
7.10 Conclusion
8 Deals and Strategic Consolidations
8.1 Industry-Wide First-in-Class Deals
8.2 Licensing Deals
8.3 Co-development Deals
9 Appendix
9.1 Abbreviations
9.2 References
9.2.1 Main
9.3 Contact Us
9.4 Disclaimer
**Note: ‘Target names in the Table of Contents have been removed until purchase’